Over the past decade, the efforts to find a cure to AD have been mainly focused on anti-amyloid agents, such as beta-secretase 1 (BACE1) inhibitors, assuming that the aggregation of amyloid-β peptides into plaques is the central triggering mechanism. This evidence concerns the gene BACE1 and Alzheimer disease.